

APPENDIX

Preventer medications registered for asthma in Singapore

Published: 15 October 2020
www.ace-hta.gov.sg



This Appendix accompanies the ACE Clinical Guidance “Asthma – optimising long-term management with inhaled corticosteroid”.

Please refer to package inserts for full details on these medications, including dose adjustments and registered uses for different age groups.


ICS (doses stated as total daily dose in micrograms)*

Beclomethasone^{†,‡}



Age (years)	Low	Medium	High
≥12	≤500	501–1000	>1000
6–11	≤200	201–400	N/A
≤5	≤200	201–400	N/A

Budesonide[†]



Age (years)	Low	Medium	High
≥12	≤400	401–800	>800
6–11	≤200	201–400	>400
≤5	≤200	N/A	N/A

Ciclesonide



Age (years)	Low	Medium	High
≥12	≤160	161–320	>320
6–11	80	81–160	>160
≤5	N/A	N/A	N/A

Fluticasone furoate



Age (years)	Low	Medium	High
≥12		100	200
6–11		50	N/A
≤5	N/A	N/A	N/A

Fluticasone propionate[†]



Age (years)	Low	Medium	High
≥12	≤250	251–500	>500
6–11	≤100	101–200	>200
≤5	≤100	N/A	N/A

Mometasone



Age (years)	Low	Medium	High
≥12	≤200	201–400	>400
6–11		100	200
≤5	100	N/A	N/A

ICS-LABA (check maximum daily dose of the LABA component; switching to an ICS-LABA inhaler with higher ICS dose per inhalation may be needed to increase the dose of the ICS component)

Beclomethasone-formoterol



Budesonide-formoterol[†]



Fluticasone furoate-vilanterol



Fluticasone propionate-formoterol



Fluticasone propionate-salmeterol[†]



Mometasone-formoterol



LAMA

Tiotropium



LTRA[§]

Montelukast



ICS, inhaled corticosteroid; LABA, long-acting beta₂ agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; N/A, not applicable

* Low, medium, and high-dose categories are based on the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention 2020,¹ local package inserts, and published trials. Doses stated do not reflect relative potency or equivalence between different ICS.

[†] Available on government subsidy list.

[‡] Low, medium, and high-dose categories stated for beclomethasone are specific to standard particle formulation. Please refer to package inserts for full details.

[§] Please refer to the Health Sciences Authority (HSA) Drug Safety Information No. 71 “Advisory on restriction on the use of montelukast and neuropsychiatric effects”.

Scan the QR code to see inhaler technique videos and other asthma resources



References

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2020. Available from: www.ginasthma.org [Accessed 15 October 2020].